Liminatus Pharma (LIMN) Enterprise Value (2024 - 2025)
Liminatus Pharma (LIMN) posted Enterprise Value of -$337655.0 for Q4 2025, up 53.39% sequentially from -$724502.0 in Q3 2025, and down 499.54% YoY from $84510.9 in Q4 2024.
Liminatus Pharma (LIMN) Enterprise Value (2024 - 2025) Analysis & Trends
Liminatus Pharma has reported Enterprise Value for 2 years, with the latest figure at -$337655.0 in Q4 2025.
- Quarterly Enterprise Value fell 499.54% year-over-year to -$337655.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$337655.0 (down 499.54% YoY) and the FY2025 annual result came in at -$337655.0, down 499.54% from the prior year.
- Enterprise Value advanced to -$337655.0 in Q4 2025 per LIMN's latest filing, from -$724502.0 in the prior quarter.
- Over five years, Enterprise Value peaked at -$34098.0 in Q2 2024 and troughed at -$724502.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Liminatus Pharma | 5.46 Mn | 5.46 Mn | - | -3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -337,655.00 |
| Sep 30, 2025 | -724,502.00 |
| Mar 31, 2025 | -34,926.00 |
| Dec 31, 2024 | -56,319.00 |
| Sep 30, 2024 | -46,979.00 |
| Jun 30, 2024 | -34,098.00 |